“It has been suggested that blood clotting could be responsible for the deterioration of lung function and death in patients with severe Covid”, said Martin Landray one of a team of scientist running Aspirin trials in relation to Covid-19. “Aspirin is inexpensive and widely used in other diseases to reduce the risk of blood clots”, Landray continued, “It is therefore disappointing that it did not have a major impact on these patient.”
“Although aspirin has been associated with a slight increase in the likelihood of leaving hospital alive, this does not seem to be sufficient to justify its widespread use for patients hospitalized with Covid-19", for its part adds Peter Horby, co-responsible for the trial via a press release on Tuesday 8 June.
The use of aspirin “is not associated with a reduction in mortality (...), the duration of hospitalization or the risk of being placed on mechanical ventilation” the report states.
The study, while not yet published, was conducted between November 2020 and March 2021 and brought together results from nearly 15,000 hospitalized patients with Covid-19.
